We use cookies necessary to giving you a better online experience. By using our website you consent to all cookies in accordance with our
Privacy Policy
.
Yes, I accept
Menu
Corporate Members
E-Library
Twitter
Linked In
Facebook
Instagram
Join
MyESTRO
Search Opener
Search for:
About ESTRO
Membership
School
Workshops
Congresses
Science
Education
Advocacy
Corporate Members
E-Library
Home
Congresses
ESTRO 2023
Programme
Lung
12 May 2023 - 16 May 2023
Vienna, Austria
ESTRO 2023
Session
Lung
Session Type:
Poster (Digital)
Track:
Clinical
Journey:
Add to
My Programme
Fractionated stereotactic radiation therapy for brain metastases: Outcomes and patterns of failure
Nuria Farre
,
Spain
Presentation Number:
PO-1303
Pattern of failure of LD-SCLC treated with chemoradiotherapy: dependence on disease stage.
Hjoerdis Hjalting Schmidt
,
Denmark
Presentation Number:
PO-1305
Response to induction chemotherapy on PET/CT predicts post-RT progression in patients with NSCLC
Marie Tvilum
,
Denmark
Presentation Number:
PO-1306
SBRT of hilar lymph nodes from lung cancer: outcomes, toxicity and role of CTV
Margherita Rotondi
,
Italy
Presentation Number:
PO-1307
Survival differences of hypofractionation vs. standard-fractionation in lung cancer: a cohort study
Macarena M. Teja Ubach
,
Spain
Presentation Number:
PO-1309
Predictors of outcomes in patients with NSCLC treated with chemoradiotherapy & immunotherapy.
Ashley Horne
,
United Kingdom
Presentation Number:
PO-1310
Epidemiological, clinical and pathological characteristics of non-small cell lung cancer in Albania
Erald Karaulli
,
Albania
Presentation Number:
PO-1314
Association between metabolic and pathologic response after neoadjuvant CRT for NSCLC
maria gonzalez de dueñas
,
Spain
Presentation Number:
PO-1315
Re-irradiation of the thorax for lung malignancy: A cohort study of cancer outcomes and toxicity
Dominic Lowe
,
United Kingdom
Presentation Number:
PO-1316
Pneumonitis after chemoRT and durvalumab: lung damage on CT is confined to the irradiated region
Gilles Defraene
,
Belgium
Presentation Number:
PO-1318
Safety and Efficacy of Moderate-intensity SBRT for Ultra-central Lung tumor
Sunmin Park
,
Korea Republic of
Presentation Number:
PO-1319
Chest Wall toxicity after lung SBRT treatments and influential parameters.
Sandra Fernandez Alonso
,
Spain
Presentation Number:
PO-1320
Early cardiac toxicity in stage III non-small cell lung cancer: preliminary dosimetric analysis
Edy Ippolito
,
Italy
Presentation Number:
PO-1322
Body composition as a predictor of an in-field recurrence in stage III NSCLC patients
Magdalena Drozka
,
Poland
Presentation Number:
PO-1324
Radiomics and Dosiomics Analysis to predict Pneumonitis after Stereotactic Radioimmunotherapy
Kim Melanie Kraus
,
Germany
Presentation Number:
PO-1327
Comparison of short-course with long-course palliative radiotherapy for superior vena cava syndrome
Jongmoo Park
,
Korea Republic of
Presentation Number:
PO-1328
Survival and prognostic factors of ultra-central tumors treated with stereotactic body radiotherapy
Viola Salvestrini
,
Italy
Presentation Number:
PO-1329
Local control rates after MR-guided single fraction SABR for lung tumors
Hilâl Tekatli
,
The Netherlands
Presentation Number:
PO-1331
Risk factors for intracranial metastasis in stage III NSCLC after chemoradiation
Stephane Thibodeau
,
Canada
Presentation Number:
PO-1332
Breath hold for photon or proton therapy in radical radiotherapy for lung cancer: worth the effort?
Judith van der Stoep
,
The Netherlands
Presentation Number:
PO-1334
Prognosticator of SBRT efficacy and toxicity in early-stage NSCLC patients
David Walz
,
Germany
Presentation Number:
PO-1336
Recent local control rates of stage I NSCLC treated with stereotactic body radiotherapy
Kenji Makita
,
Japan
Presentation Number:
PO-1337
SBRT for early-stage lung cancer: outcomes from biopsy-proven and unproven lung lesions
Celia Nicolas-Boluda
,
Spain
Presentation Number:
PO-1338
Comparing intra- and inter-fraction motion of tumors with fiducial markers for lung SBRT
Yuki Manabe
,
Japan
Presentation Number:
PO-1339
Radiation therapy in patients with non-small cell lung cancer and interstitial lung abnormalities
Makoto Ito
,
Japan
Presentation Number:
PO-1340
Failure patterns after stereotactic body radiotherapy for lung cancer according to the T stage
Hiroshi Doi
,
Japan
Presentation Number:
PO-1341
E-Mail Address
Please enter a user name
Password
Cancel
Forgotten Password
Create MyESTRO Account
i
Please log in to add this session to your programme.